Role of vemurafenib in the treatment of disseminated skin melanoma


Cite item

Full Text

Abstract

Up to date, therapy of disseminated skin melanoma remains a serious issue. In this review authors describe the main features of melanoma epidemiology, general approaches in the systemic therapy of disseminated forms of the disease. Special attention is paid to molecular-genetic mechanisms in the pathogenesis of melanoma. This publication describes the results of novel BRAF-kinase inhibitor targeted drug vemurafenib clinical trials, its safety profile and adverse reactions management. The authors also discuss the further perspectives for vemurafenib use in the therapy of skin melanoma.

About the authors

L V Demidov

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

д-р мед. наук, проф., зав. отд-нием биотерапии опухолей НИИ клинической онкологии

I A Utyashev

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

врач-онколог, науч. сотр. отд-ния биотерапии опухолей НИИ клинической онкологии

G Yu Kharkevich

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

канд. мед. наук, вед. науч. сотр. отд-ния биотерапии опухолей НИИ клинической онкологии

References

  1. World Health Organization. Skin cancers. Available from www.who.int (last accessed September 15, 2011).
  2. Ferlay J, Shin H.R, Bray F et al. GLOBOCAN 2008; 1, 2. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: on International Agency for Research on Cancer 2010.
  3. Злокачественные новообразования в России в 2010 г. (заболеваемость и смертность). Под ред. В.И.Чиссова, В.В.Старинского, Г.В.Петровой. М.: ФГБУ МНИОИ им. П.А.Герцена. 2012; ISBN 978-5-85502-154-7.
  4. Lotze M.T, Dallal R.M, Kirkwood J.M, Flickinger JC. Cutaneous melanoma. In De Vita V.T, Rosenberg S.A, Hellman S (eds.), Principles and Practice of Oncology, 6 th ed. Philadelphia: Lippincott, 2001.
  5. Bleyer A, O’Leary M, Barr R, Ries L.A.G. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000.
  6. Bethesda, M.D: National Cancer Institute; 2006. American Cancer Society. Cancer Facts & Figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed January 31, 2013
  7. Australian Institute of Health and Welfare and Australasian Association of Cancer Registries (2008). Cancer in Australia: an overview, 2008. AIHW cat. no. CAN 32.
  8. AIHW 2012. Cancer in Australia 2012: an overview. Cancer series no. 74. Cat. no. CAN 70. Canberra: AIHW.
  9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology TM Melanoma V2.2013.
  10. Харкевич Г.Ю., Демидов Л.В. Современный взгляд на лекарственное лечение диссеминированной меланомы кожи. (Практ. рекомендации общества онкологов - химиотерапевтов по диагностике, лечению и наблюдению больных меланомой кожи). Практ. онкология. 2012; 13 (2).
  11. Keilholz U, Martus P, Punt C.J. Prognostic factors for survival and factors associated with long - term remission in patients with advanced melanoma receiving cytokine - based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-a2a (IFN - a) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002; 38: 1501–11.
  12. Deroose J.P, Eggermont A.M, van Geel A.N et al. 20 years experience of TNF - based isolated limb perfusion for in - transit melanoma metastases: TNF dose matters. Ann Surg Oncol 2012; 19 (2): 627–35.
  13. Hodi F.S, O’Day S.J, Mc Dermott D.F et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23 (Erratum, N Engl J Med 2010; 363: 1290).
  14. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517–26.
  15. Davies H, Bignell G.R, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54.
  16. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445: 851–7.
  17. Omholt K, Platz A, Kanter L et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 2003; 9: 6483–8.
  18. Mandalà M, Voit C. Targeting BRAF in melanoma: Biological and clinical challenges. Crit Rev Oncol Hematol 2013; pii: S1040-8428(13)00029-2
  19. Flaherty K.T, Puzanov I, Kim K.B et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809–19.
  20. Sosman J.A, Kim K.B, Schuchter L et al. Survival in BRAFV600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366 (8): 707–14.
  21. Chapman P.B, Hauschild A, Robert C et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAFV600E mutation. N Engl J Med 2011; 364 (26): 2507–16.
  22. Paul B. Chapman, Axel Hauschild, Caroline Robert et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open - label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012; 30 (Suppl; abstr. 8502).
  23. Mc Arthur G. et al. Efficacy of vemurafenib in BRAF V600K mutation positive melanoma disease – results from the phase 3 clinical study BRIM3; presented at SMR 2012.
  24. Gonzalez R, Ribas A, Daud A et al. Phase Ib study of vemurafenib in combination with the MEK - inhibitor, GDC-0973, in patients (pts) with unresectable or metastatic BRAFV600 mutated melanoma (BRIM-7). Ann Oncol 2012; 23 (Suppl. 9); doi: abstract LBA28_PR, ixe 19. doi: 10.1093/annonc/mds499

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies